NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

An Observational Study of the Safety of Herceptin Given Subcutaneously in Patients With Early HER2-positive Breast Cancer

NCT02286362

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Breast Cancer

Countries: France

This non-interventional prospective study will assess the safety of Herceptin SC (subcutaneous administration) as used in routine clinical practice. Patients with HER2-positive early breast cancer, naive and non-naive of HER2+ treatment who are to be treated in the neoadjuvant and adjuvant setting and scheduled to initiate a treatment with Herceptin SC in routine clinical practice use are eligible to participate. The total study duration is anticipated to be 38 months.

Eligibility overview

Sex: FEMALE

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Aged \>/= 18 years
* Patients with HER2-positive early breast cancer who according to national guidelines are eligible for neoadjuvant or adjuvant HER2+ treatment
* Patients for whom the investigator has decided to start a treatment with Herceptin SC
* Trastuzumab treatment naive or non-naive (previously intravenous treatment)
* Informed consent

Exclusion Criteria:

* Patients previously treated with Herceptin SC treatment

Locations (97)

Agen, France
Aix-en-Provence, France
Aix-en-Provence, France
Aix-en-Provence, France
Albi, France
Albi, France
Antony, France
Aurillac, France
Auxerre, France
Bastia, France
Bastia, France
Bayonne, France
Besançon, France
Beuvry, France
Béziers, France
Bobigny, France
Bordeaux, France
Bordeaux, France
Bourg-en-Bresse, France
Brest, France
Brest, France
Briis-sous-Forges, France
Cannes, France
Carcassonne, France
Carcassonne, France
Challes-les-Eaux, France
Champigny-sur-Marne, France
Cholet, France
Clamart, France
Compiègne, France
+ 67 more on CT.gov